(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
4 days till quarter result
(tns 2024-05-08)
Expected move: +/- 0.00%
0.25% $ 11.90
Live Chart Being Loaded With Signals
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan...
Stats | |
---|---|
Volumen de hoy | 46 396.00 |
Volumen promedio | 44 719.00 |
Capitalización de mercado | 13.73B |
EPS | $0 ( 2024-01-29 ) |
Próxima fecha de ganancias | ( $0 ) 2024-05-08 |
Last Dividend | $0.121 ( 2021-09-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | 14.17 |
ATR14 | $0.0220 (0.18%) |
Volumen Correlación
Shionogi & Co., Ltd. Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Shionogi & Co., Ltd. Correlación - Moneda/Commodity
Shionogi & Co., Ltd. Finanzas
Annual | 2023 |
Ingresos: | $426.68B |
Beneficio Bruto: | $356.58B (83.57 %) |
EPS: | $621.31 |
FY | 2023 |
Ingresos: | $426.68B |
Beneficio Bruto: | $356.58B (83.57 %) |
EPS: | $621.31 |
FY | 2022 |
Ingresos: | $335.14B |
Beneficio Bruto: | $272.41B (81.28 %) |
EPS: | $378.75 |
FY | 2021 |
Ingresos: | $297.18B |
Beneficio Bruto: | $244.65B (82.33 %) |
EPS: | $91.26 |
Financial Reports:
No articles found.
Shionogi & Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.124 | 2021-03-29 |
Last Dividend | $0.121 | 2021-09-28 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $0.245 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.75 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.97 | |
Div. Directional Score | 9.09 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
CSNVY | Ex Dividend Junior | 2023-05-19 | Annually | 0 | 0.00% | |
TKAGY | Ex Dividend Junior | 2023-06-12 | Annually | 0 | 0.00% | |
IESFY | Ex Dividend Knight | 2023-05-16 | Semi-Annually | 0 | 0.00% | |
AZIHY | Ex Dividend Junior | 2023-05-25 | Annually | 0 | 0.00% | |
PPWLM | Ex Dividend Junior | 2023-07-19 | Quarterly | 0 | 0.00% | |
ECTM | Ex Dividend Junior | 2023-05-19 | Quarterly | 0 | 0.00% | |
UUGRY | Ex Dividend Junior | 2023-06-22 | Semi-Annually | 0 | 0.00% | |
KGFHY | Ex Dividend Knight | 2023-10-12 | Annually | 0 | 0.00% | |
BTVCY | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
SATLF | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.363 | 1.500 | 2.73 | 4.10 | [0 - 0.5] |
returnOnAssetsTTM | 0.114 | 1.200 | 6.21 | 7.46 | [0 - 0.3] |
returnOnEquityTTM | 0.132 | 1.500 | 9.64 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.288 | -1.000 | 7.12 | -7.12 | [0 - 1] |
currentRatioTTM | 6.57 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.74 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.47 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00724 | -1.500 | 9.88 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 16.34 | 1.000 | 5.06 | 5.06 | [3 - 30] |
operatingCashFlowPerShareTTM | 445.43 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 362.35 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00826 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.851 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.383 | 1.000 | 4.35 | 4.35 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 13.06 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.313 | 0.800 | -1.249 | -0.999 | [0.5 - 2] |
Total Score | 12.21 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.39 | 1.000 | 9.76 | 0 | [1 - 100] |
returnOnEquityTTM | 0.132 | 2.50 | 9.77 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 362.35 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.00474 | 1.500 | 9.88 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 445.43 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.288 | 1.500 | 7.12 | -7.12 | [0 - 1] |
pegRatioTTM | -0.00227 | 1.500 | -3.35 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.302 | 1.000 | 4.94 | 0 | [0.1 - 0.5] |
Total Score | 5.97 |
Shionogi & Co., Ltd.
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico